A detailed history of First Heartland Consultants, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, First Heartland Consultants, Inc. holds 5,475 shares of GILD stock, worth $482,238. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,475
Previous 4,011 36.5%
Holding current value
$482,238
Previous $294,000 27.89%
% of portfolio
0.03%
Previous 0.03%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$63.15 - $72.88 $92,451 - $106,696
1,464 Added 36.5%
5,475 $376,000
Q1 2024

May 07, 2024

BUY
$71.58 - $87.29 $9,019 - $10,998
126 Added 3.24%
4,011 $294,000
Q4 2023

Feb 08, 2024

BUY
$73.27 - $83.09 $6,447 - $7,311
88 Added 2.32%
3,885 $415,000
Q3 2023

Nov 09, 2023

BUY
$73.94 - $80.67 $1,256 - $1,371
17 Added 0.45%
3,797 $285,000
Q2 2023

Jul 26, 2023

SELL
$76.01 - $86.7 $267,403 - $305,010
-3,518 Reduced 48.2%
3,780 $291,000
Q1 2023

Apr 17, 2023

SELL
$77.31 - $88.08 $5,179 - $5,901
-67 Reduced 0.91%
7,298 $605,000
Q4 2022

Jan 13, 2023

SELL
$62.32 - $89.47 $32,904 - $47,240
-528 Reduced 6.69%
7,365 $0
Q3 2022

Oct 20, 2022

SELL
$59.54 - $68.01 $69,423 - $79,299
-1,166 Reduced 12.87%
7,893 $486,000
Q2 2022

Jul 12, 2022

BUY
$57.72 - $65.01 $72,496 - $81,652
1,256 Added 16.1%
9,059 $559,000
Q1 2022

Apr 21, 2022

BUY
$57.92 - $72.58 $32,203 - $40,354
556 Added 7.67%
7,803 $463,000
Q4 2021

Feb 11, 2022

SELL
$64.88 - $73.64 $19,918 - $22,607
-307 Reduced 4.06%
7,247 $526,000
Q3 2021

Nov 15, 2021

BUY
$67.69 - $73.03 $76,422 - $82,450
1,129 Added 17.57%
7,554 $528,000
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $120,593 - $131,765
1,900 Added 41.99%
6,425 $442,000
Q1 2021

May 17, 2021

BUY
$60.0 - $68.46 $37,320 - $42,582
622 Added 15.94%
4,525 $292,000
Q4 2020

Jan 29, 2021

SELL
$56.65 - $64.55 $4,815 - $5,486
-85 Reduced 2.13%
3,903 $227,000
Q3 2020

Oct 21, 2020

BUY
$62.1 - $78.08 $29,932 - $37,634
482 Added 13.75%
3,988 $252,000
Q2 2020

Jul 16, 2020

SELL
$72.34 - $84.0 $16,131 - $18,732
-223 Reduced 5.98%
3,506 $270,000
Q1 2020

May 14, 2020

BUY
$62.63 - $80.22 $233,547 - $299,140
3,729 New
3,729 $279,000
Q2 2018

Aug 09, 2018

SELL
$64.88 - $75.68 $197,624 - $230,521
-3,046 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $218 - $266
-3 Reduced 0.1%
3,046 $230,000
Q4 2017

Feb 26, 2018

SELL
$71.15 - $83.52 $418,219 - $490,930
-5,878 Reduced 65.85%
3,049 $218,000
Q3 2017

Nov 15, 2017

BUY
$72.11 - $85.47 $643,725 - $762,990
8,927
8,927 $723,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track First Heartland Consultants, Inc. Portfolio

Follow First Heartland Consultants, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Heartland Consultants, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Heartland Consultants, Inc. with notifications on news.